<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There is accumulating evidence that the natural history of <z:e sem="disease" ids="C0011869" disease_type="Disease or Syndrome" abbrv="">diabetic eye disease</z:e> is sufficiently slow that 2-yearly <z:chebi fb="46" ids="15035">retinal</z:chebi> screening, or even longer, may be safe for some patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The information technology underpinning call-recall systems within screening programmes permits a more sophisticated approach to organizing <z:chebi fb="46" ids="15035">retinal</z:chebi> screening, as directed by the clinical evidence </plain></SENT>
<SENT sid="2" pm="."><plain>This commentary explores the evidence for moving towards a biennial <z:chebi fb="46" ids="15035">retinal</z:chebi> screening programme for patients with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:mp ids='MP_0002055'>diabetes</z:mp> duration of less than 10 years. © 2012 The Authors </plain></SENT>
<SENT sid="3" pm="."><plain>Diabetic Medicine © 2012 <z:mp ids='MP_0002055'>Diabetes</z:mp> UK </plain></SENT>
</text></document>